Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: A meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zhou, Mingyi ^a   Yu, Ping ^a   Qu, Xiujuan ^a   Liu, Yunpeng ^a   Zhang, Jingdong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ABSCESS; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM INFECTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FISTULA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891900633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081858     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
2. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236. doi:10.3322/caac.20121. PubMed: 21685461.
3. Sledge GW Jr., Miller KD (2002) Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 26: 1-60. doi:10.1016/S0147-0272(02)50025-8. PubMed: 11961506.
4. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6. doi:10.1093/jnci/82.1.4. PubMed: 1688381.
5. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102: 140-144. doi:10.1016/j.ygyno.2006.05.006. PubMed: 16790264.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. doi:10.1056/NEJMoa032691. PubMed: 15175435.
7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434. doi:10.1056/NEJMoa021491. PubMed: 12890841.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191. doi:10.1200/JCO.2004.11.022. PubMed: 15169807.
9. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C et al. (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17: 771-776. doi:10.1111/j.1525-1438.2007. 00886.x. PubMed: 17343605.
10. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171. doi:10.1200/JCO.2007.11.5345. PubMed: 18024863.
11. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186. doi:10.1200/JCO.2007.12.0782. PubMed: 18024865.
12. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82. doi:10.1200/JCO.2007.12.1939. PubMed: 18165643.
13. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K et al. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110: 49-55. doi:10.1016/j.ygyno. 2008.05.030. PubMed: 18423560.
14. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN et al. (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28: 154-159. doi:10.1200/JCO.2009.22.7900. PubMed: 19917843.
15. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS et al. (2011) Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 117: 3731-3740. doi:10.1002/cncr.25967. PubMed: 21815133.
16. Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H et al. (2011) Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 29: 4662-4668. doi:10.1200/JCO.2011.36.1352. PubMed: 22067389.
17. del Carmen MG, Micha J, Small L, Street DG, Londhe A et al. (2012) A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 126: 369-374. doi:10.1016/j.ygyno.2012.05.028. PubMed: 22659190.
18. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483. doi:10.1056/NEJMoa1104390. PubMed: 22204724.
19. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496. doi:10.1056/NEJMoa1103799. PubMed: 22204725.
20. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG et al. (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039-2045. doi:10.1200/JCO.2012.42.0505. PubMed: 22529265.
21. Pujade-Lauraine E, Hilpert F, Weber B, Weber B, Reuss A et al. (2012) AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. Presented at The American Society Of Clinical Oncology Annual Meeting, Chicago, IL, June. pp. 1-5.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. doi:10.1016/S0197-2456(96)90740-0. PubMed: 8721797.
23. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10: 101-129. doi:10.2307/3001666.
24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. doi:10.1186/1745-6215-8-16. PubMed: 17555582.
25. Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P et al. (2010) Using bevacizumab to treat metastatic cancer: UK consensus guidelines. Br J Hosp Med (Lond) 71: 670-677. PubMed: 21135762.
26. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S et al. (2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev: CD: 007930. PubMed: 21901715.
27. Ye Q, Chen HL (2013) Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet, 288: 655-666. PubMed: 23543268.
28. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27: 199-205. doi:10.1200/JCO.2008.17.7931. PubMed: 19064978.
29. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL et al. (2011) Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 47: 2387-2395. doi:10.1016/j.ejca.2011.06.018. PubMed: 21757334.
30. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550. doi:10.1056/NEJMoa061884. PubMed: 17167137.
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676. doi:10.1056/NEJMoa072113. PubMed: 18160686.
32. Bear HD, Tang G, Rastogi P, Geyer CE Jr., Robidoux A et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366: 310-320. doi:10.1056/NEJMoa1111097. PubMed: 22276821.
33. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H et al. (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299-309. doi:10.1056/NEJMoa1111065. PubMed: 22276820.
34. Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A et al. (2012) Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 23: 1130-1137. doi:10.1093/annonc/mdr432. PubMed: 21976387.